Fish Skin
Diabetic Ulcers
Clinical Trial
Sigurdsson et al.
NEJM Evidence, 2024
Key Finding: Landmark multicenter randomized controlled trial — the largest ever conducted on diabetic foot ulcers with exposed bone or tendon. Enrolled 255 patients at 15 care centers across four countries. Demonstrated the efficacy and safety of intact fish skin graft treatment for the most challenging diabetic wounds.
Fish Skin
Diabetic Ulcers
Clinical Trial
Dardari et al.
Diabetes & Metabolism, 2025
Key Finding: Randomized controlled trial demonstrating 41.6% complete closure with fish skin grafts versus 22.2% standard of care at 16 weeks. 2.11x higher epithelialization rate by week 20, indicating accelerated tissue regeneration.
Fish Skin
Diabetic Ulcers
Clinical Trial
Lullove et al.
Wounds, 2022
Key Finding: Prospective, multicenter, randomized controlled trial of 94 patients. At 12-week follow-up, healing achieved in 63.0% of DFUs treated with acellular fish skin grafts compared with 31.3% in the collagen alginate control group (P=.0036). Median 6 graft applications to achieve healing.
Fish Skin
Diabetic Ulcers
Tan & Chng
Cureus, 2025
Key Finding: Six diabetic foot ulcer patients treated with fish skin grafts and negative pressure wound therapy achieved 100% healing rates with 80.5% reduction in wound surface area by 12 weeks.
Fish Skin
Diabetic Ulcers
Lee et al.
Journal of Wound Care, 2024
Key Finding: Retrospective analysis showing 82% healing rate with fish skin grafts compared to 45% standard care, even in challenging ischemic ulcer cases with compromised peripheral circulation.
Fish Skin
Diabetic Ulcers
Zhao & Shen
World Journal of Diabetes, 2025
Key Finding: Fish skin grafts demonstrated significantly accelerated wound closure timelines and reduced frequency of dressing changes compared to standard diabetic foot ulcer protocols, improving patient comfort and reducing healthcare burden.
Fish Skin
Diabetic Ulcers
Jugnet et al.
World Journal of Diabetes, 2024
Key Finding: Complete healing of a deep diabetic foot ulcer with tendon involvement in just 10 weeks using fish skin graft therapy, where traditional therapies typically require extended treatment periods.
Fish Skin
Diabetic Ulcers
Venous Ulcers
Clinical Trial
Zehnder & Blatti
Int J Lower Extremity Wounds, 2022
Key Finding: Outcome-based model from a Swiss hospital: fish skin grafts assigned to treatment-resistant VLUs and DFUs healed wounds faster than standard of care predictions, with majority healing >50% sooner than modeled timelines.
Fish Skin
Diabetic Ulcers
Venous Ulcers
Liden et al.
Wounds, 2024
Key Finding: Retrospective chart review of 131 wounds comparing PLA, fish skin grafts, and collagen dressings in DFU and VLU management. All advanced therapies outperformed standard care, with fish skin grafts showing strong closure rates across both wound types.
Fish Skin
Burns
Clinical Trial
Heitzmann et al.
Journal of Burn Care & Research, 2026
Key Finding: Prospective randomized trial comparing fish skin grafts to Suprathel synthetic dressing. Fish skin demonstrated superior scar quality at 12-month follow-up, indicating better long-term aesthetic and functional outcomes.
Fish Skin
Burns
Clinical Trial
Heitzmann et al.
Burns, 2025
Key Finding: Fish skin grafts significantly reduced healing time in burn wounds, achieving complete closure in 17 days compared to 23 days with standard dressings—a 26% acceleration in healing time.
Fish Skin
Burns
Mechanism & Safety
El Araby et al.
Journal of Clinical Medicine, 2025
Key Finding: Comprehensive systematic review demonstrating effectiveness of fish skin grafts for burn treatment across diverse healthcare settings, including resource-limited environments.
Fish Skin
Burns
Mechanism & Safety
Ivana & Sanjaya
European Burn Journal, 2025
Key Finding: Large case series of 158 burn patients treated with fish skin grafts showed only 1 infection among 114 patients (0.88% rate). Excellent safety profile supporting use in complex burn care settings.
Fish Skin
Burns
Cherry et al.
Journal of Clinical Medicine, 2023
Key Finding: Pediatric burn patients treated with fish skin grafts showed zero hypertrophic scarring—a critical finding for pediatric burn care where minimizing scarring is paramount.
Fish Skin
Burns
Posner et al.
Cureus, 2024
Key Finding: Case report of a 41-year-old with necrotizing fasciitis of the forearm treated with fish skin xenograft. Rapid epithelialization and decreased pain without additional skin grafting, highlighting potential in acute complex wounds.
Fish Skin
Mechanism & Safety
Seth et al.
Surgical Technology International, 2022
Key Finding: Comprehensive review exploring the role of omega-3 fatty acids in wound regeneration. Acellular fish skin grafts contain substantial EPA and DHA profiles that alter the inflammatory profile of wounds and provide barrier protection against bacteria.
Fish Skin
Mechanism & Safety
Kotronoulas et al.
Prostaglandins, Leukotrienes and Essential Fatty Acids, 2021
Key Finding: Biochemical analysis revealing rich omega-3 fatty acid profiles in fish skin. EPA and DHA generate anti-inflammatory lipid mediators that reduce inflammation and promote tissue regeneration.
Fish Skin
Mechanism & Safety
Liu et al.
Journal of Functional Biomaterials, 2025
Key Finding: Atlantic cod skin demonstrates faster healing rates than tilapia-derived products. Specific fatty acid composition and protein structures in cod skin provide superior biological activity.
Fish Skin
Mechanism & Safety
Magnusson et al.
Int J Lower Extremity Wounds, 2018
Key Finding: Immunological assessment confirming no autoimmune response or rejection with fish skin grafts despite xenogeneic origin. Excellent biocompatibility enabling use in diverse patient populations.
Fish Skin
Mechanism & Safety
Borra et al.
Scientific Reports, 2025
Key Finding: 28-day biocompatibility assessment demonstrating sustained high biocompatibility of fish skin grafts. No cytotoxicity or adverse biological reactions throughout extended integration period.
Fish Skin
Mechanism & Safety
Karhana & Khan
Dermatology Practical & Conceptual, 2025
Key Finding: Comprehensive systematic review synthesizing evidence across multiple wound types, confirming consistent superiority of fish skin grafts compared to standard care across diverse clinical applications.
Fish Skin
Mechanism & Safety
Clinical Trial
Kirsner et al.
Wound Repair and Regeneration, 2019
Key Finding: 170 acute wounds randomized to fish skin or dehydrated human amnion/chorion membrane. Fish skin healed significantly faster (hazard ratio 2.37; P=0.0014), demonstrating superiority over allograft alternatives.
Silk Fibroin
Clinical Trial
Rouhani et al.
Plastic and Reconstructive Surgery, 2024
Key Finding: Randomized single-blind clinical trial on 50 patients: silk fibroin dressing showed 0% erythema vs. 20.8% with Steri-Strips (P=0.002). Breast triple-point separation reduced from 30.2% to 9.3% (P=0.012). Zero total detachment of silk dressing vs. 75% Steri-Strip detachment.
Silk Fibroin
Mechanism & Safety
Clinical Trial
Zhang et al.
Advanced Healthcare Materials, 2017
Key Finding: Randomized single-blind parallel controlled clinical trial with 71 patients. Silk fibroin film significantly reduced time to wound healing and incidence of adverse events compared to commercial dressings. Preceded by successful rabbit and porcine preclinical studies.
Silk Fibroin
Mechanism & Safety
Clinical Trial
Vogt et al.
Innovative Surgical Sciences, 2024
Key Finding: Landmark study reporting first human use of silk fibroin for wound closure. Zero adverse reactions, excellent biocompatibility, minimal inflammation, and superior tissue approximation compared to traditional sutures.
Silk Fibroin
Mechanism & Safety
Burns
Liebsch et al.
Burns, 2018
Key Finding: In vivo sheep model: minimal inflammatory cytokine release with silk fibroin. Demonstrated capillary ingrowth, keratinocyte and fibroblast migration on silk fibers, and thicker epidermis formation in treated wounds. Highly biocompatible.
Silk Fibroin
Mechanism & Safety
Setooni et al.
Int J Lower Extremity Wounds, 2018
Key Finding: Silk fibroin dressing evaluated in rabbit wound model showed increased fibroblast counts, blood vessel formation, faster wound closure, and greater epidermal thickness compared to untreated and phenytoin controls.
Silk Fibroin
Mechanism & Safety
Sun et al.
Int J Molecular Sciences, 2021
Key Finding: Comprehensive review of silk fibroin's physicochemical and mechanical properties. Documents outstanding biocompatibility, biodegradability, and bioresorbability for tissue engineering including skin and wound healing applications.
Silk Fibroin
Mechanism & Safety
Chouhan & Mandal
Acta Biomaterialia, 2019
Key Finding: Critical overview documenting silk's role in cell migration, proliferation, angiogenesis, and re-epithelialization. Reviews silk fibroin, sericin, recombinant silk fibroin, and silkworm silk materials, with clinical translation evidence.
Silk Fibroin
Mechanism & Safety
Franco et al.
Biomaterials, 2022
Key Finding: Antimicrobial peptide-functionalized silk fibroin demonstrated 5-log reduction in MRSA viability. Integrated antimicrobial activity provides inherent infection prevention for surgical and wound closure applications.
Silk Fibroin
Mechanism & Safety
Yan et al.
Regenerative Biomaterials, 2025
Key Finding: Silk fibroin protein incorporated into PLLA nanofiber dressing: 16.3% increase in blood vessel count, 118.6% increase in vascular branching, 32.8% increase in total vessel length, and 29% improved wound healing rate.
Silk Fibroin
Mechanism & Safety
Chen et al.
ACS Biomaterials Science & Engineering, 2024
Key Finding: PLGA membranes reinforced with recombinant silk fibroin are noncytotoxic, significantly enhance cell migration and wound closure, and do not trigger inflammatory response—ideal for advanced wound healing.
Silk Fibroin
Burns
Chouhan et al.
ACS Biomaterials Science & Engineering, 2019
Key Finding: Silkworm silk scaffolds coated with recombinant silk fibroin demonstrated accelerated full-thickness burn wound healing in rat models, outperforming commercial DuoDERM dressings with superior vascularization and re-epithelialization.
Silk Fibroin
Burns
Mechanism & Safety
Baoyong et al.
Burns, 2010
Key Finding: Recombinant silk fibroin protein membranes significantly promoted recovery of burn wounds by increasing expression of bFGF growth factor and hydroxyproline content, outperforming collagen controls (P<0.01).
Silk Fibroin
Diabetic Ulcers
Chouhan et al.
ACS Biomaterials Science & Engineering, 2019
Key Finding: In vivo rabbit model: silk fibroin mats coated with antimicrobial and cell-binding silk fibroin proteins showed accelerated diabetic wound healing, early granulation tissue, re-epithelialization, and efficient matrix remodeling.
Silk Fibroin
Diabetic Ulcers
Ye et al.
Carbohydrate Polymers, 2025
Key Finding: Silk fibroin protein with bacterial cellulose and chitosan hydrogel achieved >98% wound closure at day 14 in diabetic rat model, outperforming both BC alone and commercial 3M Tegaderm dressing.
Silk Fibroin
Diabetic Ulcers
Mechanism & Safety
Chan et al.
Int J Biological Macromolecules, 2025
Key Finding: Silk fibroin hydrogel promotes diabetic wound healing through immune modulation (M1 to M2 macrophage polarization), ROS reduction, enhanced collagen deposition, and stimulated angiogenesis in STZ-induced diabetic mice.
Silk Fibroin
Mechanism & Safety
Abd El-Aziz et al.
Nanomedicine, 2022
Key Finding: Spidroin-based nanoparticles demonstrated reduced wound healing time and enhanced tissue regeneration. Nanoformulation increases bioavailability and therapeutic efficacy of silk fibroin proteins.
Silk Fibroin
Mechanism & Safety
Chouhan et al.
ACS Applied Materials & Interfaces, 2018
Key Finding: Functionalized silk fibroin coatings on silk fibroin scaffolds demonstrate improved cell adhesion, antimicrobial activity, and growth factor stimulation. Bilayered tissue construct with keratinized epidermis achieved in vitro.
Non-Opioid Pain
Clinical Trial
Viscusi et al.
Regional Anesthesia & Pain Medicine, 2019
Key Finding: Phase III RCT of 412 patients. HTX-011 (ZYNRELEF) demonstrated statistically significant superiority on all primary and key secondary endpoints versus bupivacaine and placebo, with sustained pain reduction through 72 hours and significantly reduced opioid consumption.
Non-Opioid Pain
Clinical Trial
Viscusi et al.
Hernia, 2019
Key Finding: Phase III RCT of 418 patients. HTX-011 reduced mean pain intensity by 23% vs. placebo and 21% vs. bupivacaine HCl. Opioid consumption reduced by 38% vs. placebo and 25% vs. bupivacaine. 51% of HTX-011 subjects were completely opioid-free through 72 hours.
Non-Opioid Pain
Clinical Trial
Lachiewicz et al.
Journal of Arthroplasty, 2020
Key Finding: Phase 2b RCT of 232 patients. Needle-free application of HTX-011 provided superior pain reduction through 72 hours after TKA compared with placebo and bupivacaine HCl, with significantly reduced postoperative opioid consumption.
Non-Opioid Pain
Mechanism & Safety
Viscusi et al.
Pain Management, 2022
Key Finding: Pooled analysis of elderly patients (≥65 years). HTX-011 was well tolerated with a safety profile similar to bupivacaine. Elderly patients reported lower postoperative pain through 72 hours and used fewer opioids, with a greater proportion remaining opioid-free compared to bupivacaine.
Non-Opioid Pain
Mechanism & Safety
Schwenk et al.
Pain Management, 2024
Key Finding: Quality improvement study at two community hospitals (July 2021–March 2023). Combination of single unilateral or bilateral nerve block with ZYNRELEF demonstrated a safe and effective multimodal approach, with no additional safety concerns identified.
Non-Opioid Pain
Clinical Trial
Minkowitz et al.
Pain and Therapy, 2021
Key Finding: Real-world randomized, open-label study demonstrating opioid-free recovery after hernia repair using HTX-011 as the foundation of a non-opioid multimodal analgesia regimen. Significantly more patients achieved opioid-free recovery compared to standard care.
Non-Opioid Pain
Mechanism & Safety
Ottoboni et al.
Regional Anesthesia & Pain Medicine, 2020
Key Finding: Biochronomer polymer technology enables controlled co-release of bupivacaine and meloxicam over 72 hours. The dual mechanism—local anesthetic blocking sodium channels plus NSAID inhibiting COX-2-mediated inflammation—provides synergistic, sustained analgesia without systemic opioid exposure.
Non-Opioid Pain
Mechanism & Safety
Bourn & Serpa
Annals of Pharmacotherapy, 2023
Key Finding: Comprehensive pharmacology review. ZYNRELEF offers a unique non-opioid approach to postoperative pain with dual-acting mechanism, needle-free application at the surgical site, and 72-hour sustained release. Positioned as a paradigm shift in multimodal perioperative analgesia.